Compare MMS & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MMS | LGND |
|---|---|---|
| Founded | 1975 | 1987 |
| Country | United States | United States |
| Employees | N/A | 68 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.7B |
| IPO Year | 1997 | N/A |
| Metric | MMS | LGND |
|---|---|---|
| Price | $60.63 | $238.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $256.29 |
| AVG Volume (30 Days) | ★ 723.3K | 176.4K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.02% | N/A |
| EPS Growth | ★ 10.42 | N/A |
| EPS | ★ 3.50 | N/A |
| Revenue | ★ $2,392,236,000.00 | N/A |
| Revenue This Year | $0.44 | $1.25 |
| Revenue Next Year | $5.15 | $19.41 |
| P/E Ratio | ★ $17.29 | $76.27 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $56.92 | $103.43 |
| 52 Week High | $100.00 | $247.38 |
| Indicator | MMS | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 41.42 | 61.82 |
| Support Level | $56.92 | $199.97 |
| Resistance Level | $63.26 | $247.38 |
| Average True Range (ATR) | 1.99 | 7.00 |
| MACD | 0.18 | 1.15 |
| Stochastic Oscillator | 58.52 | 91.53 |
Maximus Inc designs, develops, and delivers programs enabling people to access vital government services. It translates health and human services public policy into operating models that achieve outcomes for governments at scale. The company covers a broad array of services, including the operation of large health insurance eligibility and enrollment programs; clinical services, including assessments, appeals, and independent medical reviews; and technology services. The company operates through the following segments: U.S. Federal Services, U.S. Services, and Outside the U.S. A majority of its revenue is derived from the U.S. Federal Services segment, which engages with various U.S. federal government agencies to deliver clinical services, maintenance services, and technology solutions.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.